Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

anastrozole

ANASTROZOLE GH

anastrozole (ANASTROZOLE GH) is a cytochrome p450 19a1 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved NMPA: clinical trials
US status approved
Patents linked 20
Pipeline programs 32
News articles 0
Drug details — anastrozole
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
32
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

anastrozole (ANASTROZOLE GH) is a cytochrome p450 19a1 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN anastrozole
Brand ANASTROZOLE GH
Mechanism Cytochrome P450 19A1 inhibitor
Target Aromatase
Route ORAL
Formulation TABLET
Originator Alphapharm Pty Ltd

Mechanism of action

Cytochrome P450 19A1 inhibitor

Primary target: Aromatase

Approval history

Authority Status Date
FDA approved —
TGA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. Anastrozole Phase 3 · United Therapeutics Europe · Breast Cancer
  2. CLEE011O12001 Phase 3 · Novartis India · HR-positive HER-2- negative Breast Cancer
  3. CLEE011O12301C Phase 3 · Novartis India · hormone receptor (HR)-positive, HER2-negative, early breast
  4. CTRIAL-IE 12-01 Phase 3 · Ningbo Cancer Hospital · Patients with 1-3 positive Nodes, Hormone Receptor-Positive
  5. D8532C00001 Phase 3 · AstraZeneca · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Ca
  6. D8534C00001 Phase 3 · AstraZeneca · Estrogen Receptor-Positive, HER-2 negative Advanced Breast C
  7. D8535C00001 Phase 3 · AstraZeneca · ER+/HER2- Early Breast Cancer
  8. D9722C00001 Phase 3 · AstraZeneca · Advanced Breast Cancer

Related & competitor drugs

Browse all drugs
  1. exemestane Cytochrome P450 19A1 inhibitor
  2. letrozole Cytochrome P450 19A1 inhibitor
  3. testolactone Cytochrome P450 19A1 inhibitor

Related patents

Browse patents Alphapharm Pty Ltd patent hub

  1. US 11793912

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11166929

    Fatty-acid based particles

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11097035

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11083823

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10869902

    Cured gel and method of making

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10814043

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10792312

    Barrier layer

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10772995

    Cross-linked fatty acid-based biomaterials

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10603153

    Hernia patch

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10322213

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10285964

    Fatty-acid based particles

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10016465

    Cured gel and method of making

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9844611

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9827352

    Cross-linked fatty acid-based biomaterials

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9827353

    Cross-linked fatty acid-based biomaterials

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9801913

    Barrier layer

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9682175

    Coating material and medical device system including same

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9427423

    Fatty-acid based particles

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9278161

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9012506

    Cross-linked fatty acid-based biomaterials

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is anastrozole?

anastrozole (ANASTROZOLE GH) is a cytochrome p450 19a1 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for anastrozole?

ANASTROZOLE GH is a marketed brand name for anastrozole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of anastrozole?

anastrozole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.